Trial Profile
Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 15 May 2023 Planned End Date changed from 6 Apr 2024 to 6 Apr 2025.
- 15 May 2023 Planned primary completion date changed from 6 Apr 2023 to 6 Apr 2024.
- 19 Feb 2022 Results (n=44) of the treatment naive arm are presented at the 2022 Genitourinary Cancers Symposium.